However, blocking ICAM-2 in vivo during IL-33-induced airway inflammation did not affect either the numbers of pulmonary ILC2s or BAL eosinophilia, suggesting that ICAM-2 — either on ILC2s or other cells — does not affect ILC2 accumulation in the lungs, at least sufficiently. This evidence concerns the gene IL33 and inflammatory response.